# A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

> **NCT04103905** · PHASE1 · COMPLETED · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 27 (actual)

## Conditions studied

- CD20-positive B Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Recombinant Humanized Monoclonal Antibody MIL62 Injection

## Key facts

- **NCT ID:** NCT04103905
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-10
- **Primary completion:** 2019-05-30
- **Final completion:** 2020-05-29
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04103905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04103905, "A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04103905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*